Merck & Co., Inc. MRK
Super Investor & Insider
10
Fondi che lo detengono
#35
Rank consenso
14.3%
% dei portafogli
$1.67B
Valore detenuto
| Fondo | % portaf. | Attività | Azioni | Valore |
|---|---|---|---|---|
| Bill Nygren · Harris Associates | 1.99% | Reduce 12.22% | 12,366,933 | $1.49B |
| Sarah Ketterer · Causeway Capital Management | 1.26% | Reduce 18.23% | 854,212 | $102.8M |
| Kahn Brothers Group · Kahn Brothers Group | 4.85% | Reduce 47.15% | 227,288 | $27.3M |
| Prem Watsa · Fairfax Financial Holdings | 1.07% | — | 172,900 | $20.8M |
| Dodge & Cox · Dodge & Cox | 0.01% | Reduce 1.56% | 136,050 | $16.4M |
| Mairs & Power · Mairs & Power | 0.06% | Reduce 3.18% | 50,348 | $6.1M |
| Christopher Bloomstran · Semper Augustus Investments | 0.64% | Add 0.43% | 44,633 | $5.4M |
| Richard Pzena · Pzena Investment Management | 0% | Reduce 24.46% | 2,511 | $302,048 |
| Thomas Russo · Gardner Russo & Quinn | 0% | Buy | 2,141 | $257,536 |
| David Katz · Matrix Asset Advisors | 0.02% | Reduce 41.61% | 1,671 | $201,005 |
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Merck & Co., Inc. operates as a leading healthcare company worldwide, specializing in the research, development, and commercialization of innovative pharmaceutical products and vaccines. Its portfolio features prominent human health pharmaceuticals such as Keytruda for oncology treatments, Welireg for specific cancer t…
SectorHealthcare
ExchangeNYSE
IndustryDrug Manufacturers - General
CountryUnited States
Employees73,000
TickerMRK
Statistics
Market Cap$283.76B
Revenue (TTM)$65.01B
Net Income$18.25B
Net Margin28.1%
EPS$7.28
P/E33.55
P/S4.47
P/B6.41
EV/EBITDA11.44
ROE18.9%
Dividend Yield2.86%
Price$114.89
Data: Twelve Data · Revenue = mcap / P/S